Skip to main content

Advertisement

Log in

Could thrombolytic approaches in acute stroke benefit from stringent selection criteria?

  • Viewpoint
  • Published:

From Nature Reviews Neurology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. [No authors listed] (1995) Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333: 1581–1587

  2. Hacke W et al. (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359: 1317–1329

    Article  CAS  Google Scholar 

  3. Clark WM et al. (1999) Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 282: 2019–2026

    Article  CAS  Google Scholar 

  4. Hacke W et al. (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274: 1017–1025

    Article  CAS  Google Scholar 

  5. Hacke W et al. (1998) Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European–Australasian Acute Stroke Study Investigators. Lancet 352: 1245–1251

    Article  CAS  Google Scholar 

  6. Butcher KS et al. (2005) Refining the perfusion–diffusion mismatch hypothesis. Stroke 36: 1153–1159

    Article  CAS  Google Scholar 

  7. Köhrmann M et al. (2006) MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol 5: 661–667

    Article  Google Scholar 

  8. [No authors listed] (1997) Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 28: 2119–2125

  9. Castellanos M et al. (2007) Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study. Stroke 38: 1855–1859

    Article  CAS  Google Scholar 

  10. Kakuda W et al. (2005) Clinical importance of microbleeds in patients receiving IV thrombolysis. Neurology 65: 1175–1178

    Article  CAS  Google Scholar 

  11. Neumann-Haefelin T et al. (2006) Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke 37: 2463–2466

    Article  Google Scholar 

  12. McCarron M et al. (2004) Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage. Lancet Neurol 3: 484–492

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alexandre B Maulaz.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maulaz, A., Martins, R., de Castro Ribeiro, M. et al. Could thrombolytic approaches in acute stroke benefit from stringent selection criteria?. Nat Rev Neurol 5, 138–139 (2009). https://doi.org/10.1038/ncpneuro1048

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro1048

  • Springer Nature Limited

This article is cited by

Navigation